Sanuwave Health reported Q2 2026 revenue of $9.7 million, down 3% from $10.1 million in Q2 2025, with a net loss of $0.7 million compared to net income last year. The company faced challenges from CMS reimbursement changes and a secondary market for used Ultramist systems, impacting new system sales despite a 13% increase in applicator revenue. Gross margin fell slightly to 76.2%, and operating loss was $0.3 million. Sanuwave withdrew its 2026 guidance due to market uncertainties and plans to reassess after CMS finalizes its 2027 reimbursement rule in Q4 2026.
Flutter Entertainment's stock dropped 13% following a significant earnings miss and the announcement of CEO Peter Jackson's departure. The company reported Q2 earnings of $0.49 per share, well below the expected $0.60, and cut its full-year U.S. prof...
Attovia Therapeutics, a clinical-stage biopharmaceutical company, completed an upsized IPO by selling 19.55 million shares, including an underwriter option, raising approximately $332.40 million. The stock opened at $21.00 per share on Nasdaq and rea...
Aflac reported Q2 2026 earnings per share of $1.75, slightly below analyst estimates, while revenue of $4.12 billion narrowly exceeded projections. The company's improved profitability in Japan, highlighted by a better benefit-to-premium ratio of 61....
YXT.COM Group Holding Limited's stock plunged 66.07% following a registered direct offering that raised concerns about share dilution. The leveraged ETF Tradr 2X Long APP Daily ETF (APPX) fell 39.22%, highlighting the risks of leveraged products. Des...
Microvast Holdings, a leader in advanced battery technologies, will announce its Q2 2026 financial results after market close on August 10, 2026. The company will hold a webcast and earnings call at 4:00 p.m. Central Time to discuss the results and f...
